Neodrop
Create
FeedDiscoverMy ChannelsAuto-publishJoin Our Discord
Neodrop
A smoother experience in the app
FeedDiscoverCreateMy Channels
Healthcare & Health Industry Wire — Week of November 3, 2026: Part D premiums jump 50%, the first DNA-plasmid immunotherapy, and an AI agent that books the appointment
2026-11-03

Healthcare & Health Industry Wire — Week of November 3, 2026: Part D premiums jump 50%, the first DNA-plasmid immunotherapy, and an AI agent that books the appointment

This week's U.S. healthcare scan covers a 50% rise in stand-alone Medicare drug-plan premiums, the first DNA-plasmid immunotherapy approval, AI agents booking appointments and AI models misreading drug doses, a judge's ruling on Medicaid work rules, and hospital deals in Oregon, Ohio and Virginia.

Healthcare & Health Industry Wire
Healthcare & Health Industry Wire@Mark Constanza

Coverage window: October 27 – November 3, 2026

This edition covers U.S. healthcare developments published or completed between October 27 and November 3, 2026.
The Food and Drug Administration (FDA) approved the first immunotherapy built from pieces of plasmid DNA, for a rare disease of the airways. Analysts at KFF put the average premium for a stand-alone Medicare drug plan at $51 next year, up 50%. ACA marketplace open enrollment began on November 1. A federal judge struck down the government's definition of which Medicaid patients are too sick to work. And a Tacoma hospital system finished absorbing five hospitals in Oregon.

1. Health-tech funding and products

Zocdoc opens its booking system to AI agents

Status: Zocdoc opened access on October 28. Registered agents are already connected.
Zocdoc now lets artificial intelligence (AI) agents connect to its booking platform, find providers, verify insurance and schedule visits for patients. 1
Agents join through Zocdoc's access network using Model Context Protocol servers, deep links and other channels. Chief strategy officer Alex Doyne called agents "a new starting point for patients seeking healthcare." 1
Traffic from agents has "at least doubled roughly every three weeks since July," Doyne said. 1
What the agents reach is the reason Zocdoc is opening up. The company runs more than 175 scheduling integrations, 10,000 insurance plans and 200,000 verified providers. 1
The terms run both ways. Zocdoc will admit agents that register and identify themselves; agents must obtain explicit patient consent before booking and protect patient and provider data. 1
Instinct, an AI personal assistant that works over text and calls, joined on the same day. Zocdoc's Care Access Network also includes Google Gemini, Amazon Health AI, Yelp and Healthgrades. 1
Insurance checks rest on Sohar Health, which Zocdoc bought last month. Sohar's interfaces automate eligibility and benefits verification, network status checks and cost estimates. 1
For patients, the question is where the answer comes from. Doyne said much of the information online is "fragmented, outdated, or inaccurate," and that an agent is only as reliable as the systems it can reach. 1

One dosing claim in 43 from popular AI models was wrong

Status: Doximity launched its tool and published the test results in the week of October 26.
Doximity, a medical networking company that also sells clinical software, put more than 8,000 dosing questions to nine widely used AI models. The questions were drawn from real physician queries. 2
At least 2.3% of the models' dosing claims were wrong. Of the errors Doximity detected, 43.8% were serious or potentially lethal. 2
The mistakes cluster in recognizable places. Models stumbled on newer drugs and on patients whose kidney function, age, weight or medical history should change the dose. 2
Units, decimal points and drugs with similar names accounted for others. 2
Doximity's answer is DoseCheck, a layer inside its Doximity Ask clinical tool. It checks a dosing claim against FDA labeling and professional guidelines using fixed rules, instead of asking a second language model to grade the first. 2
The company says its accuracy passes 99%. DoseCheck is free and now runs for all Doximity Ask users on mobile and desktop. 2
"AI is probabilistic. Drug dosing can't be," said Louis-Antoine Mullie, Doximity's chief AI researcher. 2
For a patient using a general chatbot, the failure list is the useful part. A missed kidney adjustment produces a plausible number, and a plausible number is easy to follow.
Loading stats card…

Three funding rounds

Status: The companies announced the rounds between October 29 and November 2.
  • StimCardio, $30 million Series A, November 2. John Slump's family office, Metis Medtech, led the round, with Catalyst Health Ventures and strategic investors. The company is developing Rhyvive, a wrist-worn device that pairs electrocardiogram and optical sensors with electrodes that stimulate the median nerve. The device is intended for at-home use after catheter ablation, to reduce recurrence of atrial fibrillation, an irregular heart rhythm. The money funds a pivotal study called NeuroPulse 2 and preparation for a De Novo submission to the FDA. Rhyvive is still under clinical investigation. 3
  • Midstream Health, $20 million Series A, October 29. The round brings total funding to $29.2 million. Midstream sells AI agents that read health-system contracts and claims to recover missed revenue. 4
  • Kivo Health, $10 million Series A, October 30. Kivo delivers virtual care for chronic obstructive pulmonary disease (COPD), a group of lung conditions that block airflow. The company will use the money for health-plan partnerships, clinical expansion and its AI platform. 5

2. Pharma and device FDA news

A DNA-plasmid immunotherapy for growths in the airway

Status: The FDA granted accelerated approval on October 30.
The approval covers Voceryq, made by Inovio Pharmaceuticals, for adults with recurrent respiratory papillomatosis (RRP). 6
RRP is a rare, chronic disease. Growths caused by human papillomavirus (HPV) types 6 and 11 form in the airways, most often on the vocal cords. 6
Patients develop hoarseness, a chronic cough and voice changes. In severe cases the growths spread down the respiratory tract and make breathing difficult. 6
Surgery removes the growths, and the virus stays in the tissue. Patients return for procedures year after year, and some cases turn cancerous over time. 6
Voceryq is the first plasmid DNA-based immunotherapy the agency has approved. It delivers two small rings of DNA, called plasmids, into the body's cells. 6
One plasmid carries instructions for specific HPV proteins. The other carries the gene for interleukin-12, a molecule that sharpens the immune response. 6
The drug is injected into muscle with a device called CELLECTRA 5PSP, which applies brief electrical pulses. That technique, electroporation, opens pores in cell membranes so the DNA can get inside. 6
The evidence comes from a single open-label trial in 32 adults, with no control group. To enroll, patients needed at least two surgeries in the prior 12 months, including one scheduled at entry. 6
Of the 26 patients who had at least three prior surgeries, seven, or 27%, needed no surgery in the first year after treatment. 6
That result is an intermediate endpoint: fewer operations. The accelerated pathway requires Inovio to run post-approval trials confirming that patients actually benefit. 6
The most common side effects were injection-site reactions, headache, fatigue, high blood pressure, nausea and dizziness. Electroporation itself can cause brief muscle contractions, temporary bleeding, lightheadedness and anxiety. 6
The agency granted Breakthrough Therapy and Orphan Drug designations, both meant to speed work on serious conditions with few options. The announcement gave no price and no launch date. 6
Loading stats card…

An over-the-counter sleep apnea device gets a permanent device code

Status: The FDA published the final order on October 30.
The FDA classified the "over-the-counter device to assess risk of sleep apnea" into class II, the middle tier of device risk, with special controls. The rule took effect the same day and is codified at 21 CFR 868.2378. 7
The device type covers consumer products that analyze sensor signals and notify people they may have sleep apnea. The device flags risk; a clinician makes the diagnosis. 7
The order draws the line explicitly. Such a device may not provide a diagnosis, replace a sleep study, help a clinician diagnose a sleep disorder or serve as an apnea monitor. 7
The device type traces back to Samsung Electronics. The company requested a De Novo classification for its Sleep Apnea Feature on May 31, 2023, and the FDA granted it on February 6, 2024. 7
What changed this week is the standing of that decision. A final order turns one company's clearance into a named device type with published special controls. 7
The next maker can now file a 510(k) premarket notification against it. That route is cheaper and shorter than a De Novo request, so the device type is open to any company that can meet the controls. 7
The special controls name the risks the agency wants handled: a false negative that delays evaluation, poor sensor data producing a wrong assessment, and users abandoning treatment they already have. 7
A consumer notification is a prompt to ask a doctor, which is how the label has to frame it. The order also requires testing in people both with and without symptoms. 7

Device and diagnostics briefs

Status: Two clearances were announced in the window; one decision record was not yet posted.
  • Roche, cobas eplex respiratory pathogen panel 3, announced November 2. Roche said the FDA cleared the test, which detects up to 19 viral and bacterial targets from a single nasopharyngeal swab. It adds Bordetella pertussis, the bacterium behind whooping cough, and updates its influenza A and SARS-CoV-2 assays for currently circulating strains. Laboratories can run up to five panel configurations, and results arrive in under two hours. The FDA's public 510(k) index had not posted this decision record as of November 3. 8
  • SEKISUI Diagnostics, OSOM COVID-19/Flu A&B Combo Test, announced October 27. The company said the FDA cleared and it launched a rapid test that detects COVID-19 and influenza A and B together. 9

3. Insurance and policy

The average stand-alone Medicare drug plan costs 50% more next year

Status: KFF published the analysis on October 30. Medicare open enrollment runs through December 7.
Medicare drug coverage comes two ways. A stand-alone Part D plan adds drug coverage to Original Medicare. A Medicare Advantage prescription drug plan bundles drugs with hospital and outpatient care. 10
For stand-alone plans, the average monthly premium rises to $51 in 2027 from $34 this year. That is a 50% increase, and it assumes the 13.6 million enrollees without low-income subsidies keep the plan they have. 10
The federal Medicare agency puts the increase at about $1, taking the national average from $35 to $36. CMS did not explain the method behind that figure, and KFF says it may assume people switch plans. 10
KFF's own history argues for caution in both directions. Last year it projected $44 for 2026, and the actual average came in at $34 after enrollees moved to cheaper plans. 10
Standing still is what costs. Three-fourths of enrollees without subsidies, 10.4 million people, will pay more in 2027 if they change nothing. 10
That group includes 4.1 million people in plans that charge no premium this year. No stand-alone Part D plan charges zero in 2027. 10
For 2.4 million of them, the increase exceeds $50 a month. Last year 38,000 enrollees faced an increase that large. 10
The spread between plans is wide. Average monthly premiums among the eight national stand-alone plans run from about $6 to $204. 10
Centene's Wellcare Value Script Rx is the cheapest at $6.50, up from $5.80. United's AARP Medicare Rx Preferred is the priciest at $204.50, up from $126. 10
Part of the jump traces to policy. The administration ended the Part D Premium Stabilization Demonstration after 2026, which had subsidized plans and capped any monthly increase at $50. 10
The premium is only one line. Most enrollees also face a deductible and coinsurance rather than fixed copays. 10
The standard Part D deductible rises to $700 from $615. The average deductible in stand-alone plans reaches $643, up from $540. 10
Coinsurance is a percentage of a drug's price, not a flat fee. The median for preferred brands in stand-alone plans is 25%, and 35% for non-preferred drugs. 10
The comparison that decides many households is drug coverage inside Medicare Advantage. Its average premium is $9, and it rises by about $2. 10
The cheaper premium buys a narrower network and more prior authorization, the requirement to get insurer approval before some care. That trade-off belongs in the same decision as the premium. 10
The menu is large enough to make shopping worthwhile. The average beneficiary can choose among 28 Medicare Advantage drug plans and 9 stand-alone plans. 10
Loading stats card…

Marketplace open enrollment for 2027 opened November 1

Status: CMS published plan data on October 30. Enrollment runs through January 15, 2027.
Open enrollment on HealthCare.gov, the federal insurance marketplace, began November 1 for coverage that starts January 1, 2027. 11
The Centers for Medicare & Medicaid Services (CMS) says more than 75% of people buying through HealthCare.gov will have access to premiums at or below $50 a month. 11
For enrollees eligible for tax credits, the agency says the federal government will cover nearly 90% of the lowest-cost premium. It puts that share at 85% in 2020. 11
Choice is wide on paper. The average shopper can pick from about 100 plans sold by five or six insurers. 11
Every shopper on HealthCare.gov now has access to plans that pair with a health savings account (HSA), a tax-advantaged account for medical costs. The agency says enrollees will find 35 such plans on average. 11
Catastrophic plans, the lowest-cost tier, run nearly 10% cheaper than the next cheapest tier. 11
These are the agency's own figures, published the day before the window opened. The share with access to a $50 premium describes what is available, not what the average enrollee pays.
One deadline from this week does not touch the coverage being sold now. CMS proposed on October 23 to verify income and other eligibility facts before paying subsidies, and that rule would first apply to 2028 coverage. 12

A judge rejects the definition of "medically frail"

Status: The ruling came on October 29 and was reported the next day. An appeal remains possible.
Medicaid work requirements start in 2027. Adults covered through the Affordable Care Act's Medicaid expansion must log 80 hours a month of work, volunteering or schooling to stay enrolled. 13
The law exempts people who are blind or disabled, and those with a substance use disorder, serious mental illness or a complex medical condition. 13
CMS rules finished this summer narrowed that group. To qualify as medically frail, a person had to be so sick as to be unable to comply with the work rules. 13
Twenty-five states and the District of Columbia sued in June. Judge Richard D. Stearns of the U.S. District Court for Massachusetts agreed that the definition went beyond what Congress wrote. 13
The judge vacated the definition and issued a permanent injunction. He left two other disputed provisions standing. 13
States may still review only claims and visit data from the past 12 months to judge frailty, and limits on how often patients can self-attest to it remain. 13
Stearns gave states six months before they must enforce frailty determinations, acknowledging the operational work involved. CMS declined to comment, citing pending litigation. 13
For a patient with a serious condition in an expansion state, the ruling restores a broader exemption. An appeal from CMS could still undo it.

Brief: a final rule on organ procurement

Status: CMS finalized the rule on October 30.
Organ procurement organizations (OPOs) secure authorization for donations, recover organs and deliver them to transplant programs. The final rule lets high-performing OPOs compete for more than one donation service area. 14
It also defines "unsound medical practices," which gives CMS a stated basis for decertifying an OPO, and requires a transition plan when one organization takes over a service area. 14
One scoring change is technical and consequential. Pancreata used only for islet cell research no longer count toward an OPO's transplant rate. 14
CMS reports 49,000 transplants in 2025 and more than 100,000 people still waiting. Since its 2020 OPO rule, donations are up 36% and transplants 30%. 14

4. Hospital M&A

MultiCare completes its takeover of Samaritan Health Services

Status: The affiliation closed on November 1, after public agencies approved it last month.
Samaritan Health Services, based in Corvallis, Oregon, joined Tacoma-based MultiCare Health System on November 1. The two announced plans to affiliate in October 2025. 15
Samaritan brings five hospitals and more than 100 clinics across a five-county area between the Cascade Mountains and the Pacific coast. It is MultiCare's first system in Oregon. 15
MultiCare now runs 18 hospitals and more than 300 clinics and urgent care centers. S&P Global Ratings puts the combined systems' revenue at about $9.1 billion. 15
MultiCare has pledged $700 million of investment in Samaritan over 10 years, directed at access, facilities and recruitment. 15
Samaritan keeps its name and local governance, and its leaders will advise on how the money is spent. The MultiCare logo went up at Samaritan Lebanon Community Hospital this week. 15
S&P notes that Samaritan holds 71% of its market with limited competition, and that it posted operating losses in fiscal 2025, smaller than the year before. 15
Market concentration of that size is the part regulators and employers watch. For patients in the Willamette Valley, the visible change arrives as construction budgets and a new parent company.

Kettering Health signs a definitive agreement for a 99-bed Ohio hospital

Status: The agreement was signed late last week and reported on November 2. Regulators must still approve it.
Kettering Health has signed a definitive agreement to acquire Knox Community Hospital, a 99-bed hospital in Mount Vernon, Ohio. 16
The two signed a letter of intent in July. They aim to close by January 1, 2027. 16
Kettering, based in the Dayton suburb of Kettering, operates 14 medical centers, more than 100 outpatient locations and a medical group in western Ohio. 16
The system pledged what it called a significant capital investment, without a dollar figure. The plans include modern equipment and technology, among them Epic's electronic health record system. 16
Knox has been losing money. It reported a $22 million loss in 2024, according to IRS records cited by the Dayton Daily News. That followed profit of about $1.6 million in 2023 and a $17.4 million loss in 2022. 16
The hospital says it came to the table from a solid financial position, and that it weighed other partners. 16
On staffing, Kettering says it intends to offer continued employment to substantially all active employees after closing. 16

Brief: a Virginia hospital changes hands

Bon Secours completed its purchase of Fauquier Health, a 97-bed hospital in Warrenton, Virginia, from Lifepoint Health on November 1. It also bought Sports Medicine & Orthopaedic Center, a three-location practice in Hampton Roads. 17
Fauquier is the 48th hospital for Bon Secours Mercy Health and extends the system's Virginia footprint to 12. Financial terms were not disclosed. The asset purchase agreement was announced in August, which this channel reported at the time. 17

5. Patient health tip

The HPV vaccine prevents the infections behind the disease this week's approval treats

The FDA's RRP approval treats adults who already have the disease. Vaccination is what keeps it from starting. 6
RRP is caused by HPV types 6 and 11, and the vaccine sold in the United States covers both. 18
That vaccine, Gardasil-9, protects against nine HPV types: 6, 11, 16, 18, 31, 33, 45, 52 and 58. 18
The Centers for Disease Control and Prevention (CDC) recommends two doses at ages 11 to 12, given six to 12 months apart, and vaccination can start at age 9. 18
Anyone who starts at 15 or older, through age 26, needs three doses over six months. People with weakened immune systems need three doses at any age from 9 to 26. 18
Adults aged 27 to 45 who were never vaccinated can decide with a doctor. The benefit is smaller in that range, because most people have already been exposed to HPV. 18
The protection is well documented. Infections with the HPV types that cause most HPV cancers and genital warts have fallen 88% among teen girls and 81% among young adult women since vaccination began in 2006. 18
Some people should skip it. People who are pregnant or allergic to yeast should not get Gardasil-9, and a prior severe allergic reaction to the vaccine rules it out. 18
Most insurance plans cover the vaccine, and the Vaccines for Children program provides it at no cost to eligible families. A doctor's office is the usual place to start; pharmacists, health departments and school clinics also give it. 18
If a child or teenager in your household has not finished the series, call the pediatric practice. Staff can check the record and book the next dose. 18

References

  1. 1
    Zocdoc opens infrastructure to AI agents

    fiercehealthcare.com

  2. 2
    Weekly Rundown: Doximity launches DoseCheck

    fiercehealthcare.com

  3. 3
    StimCardio garners $30M for wearable atrial fibrillation therapy

    mobihealthnews.com

  4. 4
    Midstream Health raises $20M for autonomous AI financial platform

    mobihealthnews.com

  5. 5
    Kivo Health raises $10M for virtual COPD care

    mobihealthnews.com

  6. 6
    FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis

    fda.gov

  7. 7
    Medical Devices; Anesthesiology Devices; Classification of the Over-the-Counter Device To Assess Risk of Sleep Apnea

    federalregister.gov

  8. 8
    Roche receives FDA 510(k) clearance for new cobas eplex respiratory pathogen panel 3

    prnewswire.com

  9. 9
    SEKISUI Diagnostics Announces 510(k) Clearance and Launch of the OSOM COVID-19/Flu A&B Combo Test

    prnewswire.com

  10. 10
    Medicare Part D Premiums and Cost Sharing in 2027

    kff.org

  11. 11
    Plan Year 2027 Marketplace Plans and Prices Fact Sheet

    cms.gov

  12. 12
    Exchange Pre-Eligibility Verification Proposed Rule (CMS 9873-P)

    cms.gov

  13. 13
    Judge strikes down CMS 'medical frailty' policy for Medicaid work requirements

    healthcaredive.com

  14. 14
    CMS Finalizes Rule to Help More Organs Reach Patients and Strengthen Accountability for Organ Procurement Organizations

    cms.gov

  15. 15
    MultiCare, Samaritan Health Services come together

    chiefhealthcareexecutive.com

  16. 16
    Ohio health system poised to add another hospital

    chiefhealthcareexecutive.com

  17. 17
    Bon Secours acquires Virginia hospital, orthopedic practice

    beckershospitalreview.com

  18. 18
    HPV Vaccination

    cdc.gov

Healthcare & Health Industry Wire
Healthcare & Health Industry Wire@Mark Constanza

This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.

Related content

  • Coverage window: October 27 – November 3, 2026
  • 1. Health-tech funding and products
  • Zocdoc opens its booking system to AI agents
  • One dosing claim in 43 from popular AI models was wrong
  • Three funding rounds
  • 2. Pharma and device FDA news
  • A DNA-plasmid immunotherapy for growths in the airway
  • An over-the-counter sleep apnea device gets a permanent device code
  • Device and diagnostics briefs
  • 3. Insurance and policy
  • The average stand-alone Medicare drug plan costs 50% more next year
  • Marketplace open enrollment for 2027 opened November 1
  • A judge rejects the definition of "medically frail"
  • Brief: a final rule on organ procurement
  • 4. Hospital M&A
  • MultiCare completes its takeover of Samaritan Health Services
  • Kettering Health signs a definitive agreement for a 99-bed Ohio hospital
  • Brief: a Virginia hospital changes hands
  • 5. Patient health tip
  • The HPV vaccine prevents the infections behind the disease this week's approval treats
Doximity's dosing test
Nine AI models, more than 8,000 physician-style dosing questions, results published the week of October 26, 2026
Dosing claims that were wrong (%)2
Detected errors rated serious or potentially lethal (%)44
Dosing questions put to the models8,000
AI models tested9
Voceryq in recurrent respiratory papillomatosis
Figures from the FDA's October 30, 2026 approval announcement
Adults in the single-arm trial (patients)32
Patients with at least three prior surgeries (patients)26
Of those, share needing no surgery in year one (%)27
DNA plasmids delivered per dose2
Part D in 2027, against 2026
KFF analysis published October 30, 2026; assumes current enrollees keep their plan
Average stand-alone monthly premium (USD)$51.00+50.0%vs 2026 ($34)
Standard Part D deductible (USD)$700.00+13.8%vs 2026 ($615)
Non-subsidized enrollees paying more if they do nothing (%)76
Stand-alone plans with a zero premium in 2027 (count)0